Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (82)

1

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma : Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial

enthalten in: The oncologist | 2023

von Larkin, J. | Oya, M. | Martignoni, M. | +16

2

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2022

von Rahma, O. | Tyan, K. | Giobbie-Hurder, A. | +11

3

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

enthalten in: Journal for immunotherapy of cancer | 2022

von Schöffski, P. | Tan, D. | Martín, M. | +29

4

Toripalimab plus axitinib in patients with metastatic mucosal melanoma : 3-year survival update and biomarker analysis

enthalten in: Journal for immunotherapy of cancer | 2022

von Li, S. | Wu, X. | Yan, X. | +17

5

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer : results from an open-label, multicenter phase 2 basket study

enthalten in: Journal for immunotherapy of cancer | 2022

von Xia, L. | Peng, J. | Lou, G. | +12

6

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma : a phase 1b study

enthalten in: Journal for immunotherapy of cancer | 2022

von Yoshikawa, A. | Yamaguchi, K. | Muro, K. | +13

7

Drugs and the FDA : a story of tragedy, effectiveness, and safety

Erschienen: Cambridge, Massachusetts, The MIT Press, [2022]

von Sekeres, M.

8

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies : results from a phase I/II open-label, multicenter study

enthalten in: Journal for immunotherapy of cancer | 2022

von Zucali, P. | Lin, C. | Carthon, B. | +22

9

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer : survival and immune correlates

enthalten in: Journal for immunotherapy of cancer | 2021

von Liao, J. | Gwin, W. | Urban, R. | +14

10

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

enthalten in: Journal for immunotherapy of cancer | 2021

von Piha-Paul, S. | Geva, R. | Tan, T. | +13

1
2
3
4
5
6
7
8
9
Nächster »
[9]